2. Academic Validation
  3. BP‑1‑102 exerts antitumor effects on T‑cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/c‑Myc signaling pathway

BP‑1‑102 exerts antitumor effects on T‑cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3/c‑Myc signaling pathway

  • Exp Ther Med. 2023 Mar 15;25(5):191. doi: 10.3892/etm.2023.11890.
Can Ye 1 2 3,  Xueqin Ruan 1 2 3,  Yan Zhao 1 2 3,  Hongkai Zhu 1 2 3,  Canfei Wang 1 2 3,  Zhao Cheng 1 2 3,  Hongling Peng 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410000, P.R. China.
  • 2 Institute of Molecular Hematology, Central South University, Changsha, Hunan 410000, P.R. China.
  • 3 Hunan Engineering Research Center of Targeted Therapy for Hematopoietic Malignancies, Changsha, Hunan 410000, P.R. China.
  • 4 Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410000, P.R. China.
PMID: 37020528 DOI: 10.3892/etm.2023.11890
Abstract

Drug resistance and relapse of T-cell acute lymphoblastic leukemia (T-ALL) remain significant concerns for physicians; hence, the development and screening of effective targeted drugs remain important. Considering that STAT3 is emerging as a potential therapeutic target for T-ALL, T-ALL cell lines (MOLT-4 and CUTLL1) were treated with BP-1-102, a small-molecule inhibitor that blocks STAT3 phosphorylation. Cell Counting Kit-8 assay and colony formation assay results showed that BP-1-102 inhibited T-ALL cell proliferation and colony formation. Flow cytometry and morphological results demonstrated that BP-1-102 dramatically induced Apoptosis and caused cell cycle arrest at the G0/G1 phase in T-ALL cell lines. Western blotting results indicated that BP-1-102 suppressed the JAK2/STAT3/c-Myc pathway activity in T-ALL cell lines. In conclusion, BP-1-102 suppressed the JAK2/STAT3/c-Myc signaling pathway in T-ALL cells and exerted various antitumor effects, representing a promising targeted antitumor inhibitor.

Keywords

STAT3; T-cell acute lymphoblastic leukemia; apoptosis; cell cycle; colony formation; proliferation; small-molecule inhibitor.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100493
    99.26%, STAT3 Inhibitor